We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MorphoSys Opens new Facilities in Oxford, UK
News

MorphoSys Opens new Facilities in Oxford, UK

MorphoSys Opens new Facilities in Oxford, UK
News

MorphoSys Opens new Facilities in Oxford, UK

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys Opens new Facilities in Oxford, UK"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG has announced that it has opened new UK headquarters in Kidlington, North Oxford. The 2,200 square meters facility acts as the new UK headquarters for the MorphoSys Group of companies situated in the UK.

The official opening ceremony was performed by UK Minister of State for Science and Innovation, Malcolm Wicks. Dr. Simon Moroney, Chief Executive Officer of MorphoSys Group, also attended along with Chief Financial Officer Dave Lemus, Head of AbD Serotec Dieter Lingelbach, Tim Bernard, Head of Sales of AbD Serotec and the Managing Director of AbD Serotec James Bernard.

According to the Company, in April 2006, on the back of its Q1 results, it announced plans to consolidate its UK operations at a single site in Oxford. The operation is now complete and the company looks forward to growing its research antibody business from this new base in the UK.

UK Minister of State for Science and Innovation, Malcolm Wicks, said: "The UK has a deserved reputation for excellence in biotechnology. This new facility demonstrates further that the UK is an attractive location for European businesses to invest. I welcome this investment by the MorphoSys Group, which links two of Europe's most successful biotech clusters, and wish the company well for its plans to grow its business in the UK and abroad."

"The Oxford region provides us with a strong infrastructure and a high concentration of excellent academic researchers and innovative biotechnology companies - both potential customers for our technology," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.

"Since the UK represents one of the top three markets for our research antibody segment operating under the AbD Serotec brand, a strong presence in this region will remain a key element of our future strategy."

Advertisement